Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.

Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M.

Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27.

2.

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.

Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M.

Int J Oncol. 2014 Oct;45(4):1381-90. doi: 10.3892/ijo.2014.2556. Epub 2014 Jul 22.

3.

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, Innocenti F, Cecchin E, Toffoli G, Guillemette C.

J Pharmacol Exp Ther. 2013 Apr;345(1):95-101. doi: 10.1124/jpet.112.202242. Epub 2013 Feb 5.

4.

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G.

J Clin Oncol. 2009 May 20;27(15):2457-65. doi: 10.1200/JCO.2008.19.0314. Epub 2009 Apr 13.

PMID:
19364970
5.

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL.

Clin Cancer Res. 2005 Feb 1;11(3):1226-36.

6.

Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H.

Jpn J Clin Oncol. 2011 Apr;41(4):477-82. doi: 10.1093/jjco/hyr001. Epub 2011 Feb 7.

PMID:
21303789
7.

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y.

Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84. doi: 10.1007/s00280-010-1485-8. Epub 2010 Oct 19.

PMID:
20957480
8.

Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.

Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, Miwa K, Kawara K, Ichikawa W, Ando Y, Saji S, Sasaki Y.

Jpn J Clin Oncol. 2011 May;41(5):617-23. doi: 10.1093/jjco/hyr010. Epub 2011 Feb 9.

PMID:
21310730
9.

Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.

Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, Ye ZB, Zhang J, Zhu ZG.

Drug Des Devel Ther. 2015 Jul 17;9:3677-83. doi: 10.2147/DDDT.S86750. eCollection 2015.

10.
11.

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM.

World J Gastroenterol. 2012 Dec 7;18(45):6635-44. doi: 10.3748/wjg.v18.i45.6635.

12.

UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.

Miyata Y, Touyama T, Kusumi T, Morita Y, Mizunuma N, Taniguchi F, Manabe M.

Int J Clin Oncol. 2016 Aug;21(4):696-703. doi: 10.1007/s10147-015-0937-x. Epub 2015 Dec 28. Erratum in: Int J Clin Oncol. 2016 Aug;21(4):704.

13.

Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.

Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C.

Drug Metab Pharmacokinet. 2016 Feb;31(1):90-4. doi: 10.1016/j.dmpk.2015.12.004. Epub 2015 Dec 31.

PMID:
26830078
14.

The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.

Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S.

J Clin Oncol. 2006 Jul 1;24(19):3061-8.

PMID:
16809730
15.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.

Manfredi S, Bouché O, Rougier P, Dahan L, Loriot MA, Aparicio T, Etienne PL, Lafargue JP, Lécaille C, Legoux JL, Le Malicot K, Maillard E, Lecomte T, Khemissa F, Breysacher G, Michel P, Mitry E, Bedenne L.

Mol Cancer Ther. 2015 Dec;14(12):2782-8. doi: 10.1158/1535-7163.MCT-15-0293. Epub 2015 Oct 22.

16.

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M.

Br J Cancer. 2011 Jun 28;105(1):53-7. doi: 10.1038/bjc.2011.206. Epub 2011 Jun 7.

17.

Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.

Hirata K, Nagata N, Kato T, Okuyama Y, Andoh H, Takahashi K, Oba K, Sakamoto J, Hazama S, Mishima H.

Anticancer Res. 2014 Jan;34(1):195-201.

PMID:
24403462
19.

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L.

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.

PMID:
23686699
20.

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F.

J Clin Oncol. 2010 Feb 10;28(5):866-71. doi: 10.1200/JCO.2009.23.6125. Epub 2009 Dec 28.

Supplemental Content

Support Center